Local Coverage DeterminationPain Management

LCD L37254: Chiropractic Services — CGS

LCD-L37254

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L37254
Published
June 5, 2026
Effective date
January 29, 2026
MAC region
CGS Administrators

Summary

The upcoming LCD for Chiropractic Services by CGS may impact billing processes, requiring providers to familiarize themselves with new documentation and code requirements to ensure compliance. Effecti

New LCD for Chiropractic Services effective January 2026.

Affected codes

ICD-10-CM

Affected specialty

Pain Management alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37254&ver=16

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

FDA Approval: DEMEROL (MEPERIDINE HYDROCHLORIDE) — Type 1 - New Molecular Entity

Policy FDA-NDA005010 · Pain Management

High

The billing pathway for DEMEROL cannot be determined until the FDA label publishes further details regarding its billing status. Billing teams should verify against the FDA label for updated informati

View alert

FDA Approval: SYNALGOS-DC (ASPIRIN) — Type 4 - New Combination

Policy FDA-NDA011483 · Pain Management

High

The billing impact of SYNALGOS-DC will be classified under Part D due to its oral route of administration. Billing teams should verify the FDA label for precise billing details as they become availabl

View alert

FDA Approval: TAPENTADOL (TAPENTADOL HYDROCHLORIDE) — Type 1 - New Molecular Entity

Policy FDA-NDA022304 · Pain Management

High

The drug tapentadol hydrochloride is administered orally and is classified under Part D of Medicare billing. Billing teams should verify against the FDA label for any specific billing details once pub

View alert

FDA Approval: OXAYDO (OXYCODONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA202080 · Pain Management

High

As OXAYDO is administered orally in tablet form, it will be billed under Part D. The exact billing details may vary, so billing teams should verify the payment methodology once the FDA label is publis

View alert